Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients. Furthermore, in cancer patients, cells collected via apheresis using Plerixafor and G-CSF have been successfully transplanted. In December 2008, Plerixafor received approval from the Food and Drug administration for use in combination with G-CSF to aid in mobilization of progenitor cells for apheresis. The proposed study is not designed to support approval of a new indication or change in the advertising for Plerixafor. The route of administration and dosage level are identical to that which is listed on the package insert. Although Plerixafor is not approved for patients with Hodgkins Lymphoma, there is no known or theoretic increased risk of the use of this drug in this patient population.

The study hypothesis for this study is that patients with a circulating CD34+ count < 20 cells/ul after 5 days of mobilization with G-CSF alone will achieve > or equal to 2 X 10(6)CD34+ cells/kg within 3 days of apheresis after receiving Plerixafor with G-CSF.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: Genzyme, a Sanofi Company
• Treatments: JM 3100; Lenograstim; Plerixafor

Criteria

Inclusion Criteria:

• Age 18 to 75 years.

• Diagnosis of NHL, HD or MM

• Eligible for autologous transplantation

• CD34+ cell count < 7 cells/ul after 5 days of mobilization with G-CSF or CD34+ cell count between 7 and 19 (inclusive) on day 5 of mobilization with G-CSF and < 1.3 x 106 CD34+ cells collected by apheresis on day 5 of G-CSF therapy.

• < or equal to 5 prior regimens of chemotherapy (Rituxan is not considered chemotherapy for the purpose of this study)

• ≥ 3 weeks since last cycle of chemotherapy and the beginning of G-CSF mobilization (Rituxan and Lenalidomide are not considered chemotherapy for the purpose of this study)

• Total dose of melphalan < or equal to 200 mg

• ECOG performance status of 0 or 1

• Recovered from all acute toxic effects of prior chemotherapy

• Absolute PMN count > 1.0 X 10(9)/l prior to first dose of G-CSF

• PLT count > 75 X 10(9)/l prior to first dose of G-CSF

• Serum creatinine < or equal to 2.5 mg/dl

• SGOT, SGPT and total bilirubin < 2 X upper limit of normal (ULN) prior to the first dose of G-CSF

• Cardiac and pulmonary status sufficient to undergo apheresis and transplantation as determined by standard institutional practice

• Signed informed consent

• Patients of childbearing potential agree to use an approved form of contraception

Exclusion Criteria:

• A co-morbid condition which, in the view of the investigator, renders the patient at high risk from treatment complications

• Failed previous stem cell collection or collection attempts

• A residual acute medical condition resulting from prior chemotherapy

• Active brain metastases or carcinomatous meningitis

• Active infection requiring antibiotic treatment (excluding controlled catheter-related bacteremia)

• Received prior radio-immunotherapy with Zevalin or Bexxar

• Received thalidomide, dexamethasone, and/or Velcade within 7 days prior to the first dose of G-CSF

• Positive pregnancy test in female patients

• Lactating females

• Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol